Interaction of antiestrogens with binding sites for muscarinic cholinergic drugs and calcium channel blockers in cell membranes

Batra S (1985) Characterization of [3H]-nitrendipine binding to uterine smooth muscle plasma membrane and its relevance to inhibition of calcium entry. Br J Pharmacol 27: 57

Batra S (1987) Comparison of muscarinic acetylcholine binding in the urinary bladder and submandibular gland of the rabbit. Eur J Pharmacol 138: 83

Batra S, Popper L (1989) Characterization of membrane calcium channels in the nonpregnant and pregnant human uterus. Gynecol Obstet Invest 27: 57

Batra S, Sjöberg N-O, Thorbert G (1978) Estrogen and progesterone interactions in the rabbit uterus in vivo after steroid administration. Endocrinology 102: 268

Bratherton DG, Brown CH, Buchanan R, Hall V, Pillers EMK, Wheeler TK, Williams CJ (1984) A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bdversus 20 mg bd. Br J Cancer 50: 199

Cheng YC, Prusoff NH (1983) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099

Criss WE, Kaiuchi S (1982) Calcium: calmodulin and cancer. Fed Proc 41: 2289

Goodlad RA, Wright NA (1989) Peptides and epithelial growth regulation. Experientia 56: 180–191

Greenberg DA, Carpenter CL, Messing RO (1987) Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC12 neurosecretory cell line. Cancer Res 47: 70

Hohn KV, Onoda JM, Diglio DA, Sloane BF (1983) Calcium channel blockers: potential antimetastatic agents. Proc Soc Exp Biol Med 174: 16

Jacobs SC, Slory MT (1988) Exocrine secretion of epidermal growth factor by rat prostate: effect of adrenergic agents, cholinergic agents and vasoactive intestinal peptide. Prostate 13: 79

Jordan VC (1984) Biochemical pharmacology of antiestrogen action. Pharmacol Rev 36: 245

Kroegar EA, Brandes LJ (1985) Evidence that tamoxifen is a histamine antagonist. Biochem Biophys Res Commun 130: 750

Lam H-YP (1984) Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun 118: 27

Lazo JS, Schwartz PE, Maclusky MJ, Labaree DC, Eisenfeld AJ (1984) Antiproliferative actions of tamoxifen of human ovarian carcinomas in vitro. Cancer Res 44: 2266

Lippman ME, Bates S, Dicksson RB, Knabbe C, Huff K, Swain S, McManaway M, Bronzert D, Kasid A, Gelmann EP (1986) Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res Treat 7: 59

Lipton A (1987) The anti-oestrogen tamoxifen is a calcium antagonist in perfused rat mesentery. Cancer Chemother Pharmacol 20: 125

Peterson GL (1979) A simplification of the protein assay method of Lowry et al. which is more generally acceptable. Anal Biochem 83: 346

Runge H-M, Teufel G, Neulen J, Geyer H, Pfleiderer A (1986) In vitro responsiveness of ovarian epithelial carcinomas to endocrine therapy. Cancer Chemother Pharmacol 16: 48

Takuwa N, Ganz M, Takuwa Y, Sterzel RB, Rusmussen H (1989) Studies of the mitrogenic effect of serotonin in rat renal mesangial cells. Am J Physiol 257: 431–439

Watts CKW, Murphy LC, Sutherland RL (1984) Microsomal binding sites for nonsteroidal anti-estrogens in MCF-7 human mammary carcinoma cells. J Biol Chem 259: 4223–4229